|
GENinCode PLC - Oxford-based genetic testing company and Thermo Fisher Scientific Inc - Waltham, Massachusetts-based life science technology firm - Thermo Fisher Scientific to sell, distribute and manufacture GENinCode’s CARDIO inCode-Score Polygenic Risk Score test for the prediction and prevention of coronary heart disease. On Thursday, the test was approved by the New York Department of Health, leading shares higher. Discussions with the US Food and Drug Administration are ongoing, and GENinCode expects to submit additional data to complete its De Novo assessment application in the first quarter of 2026. The Thermo Fisher agreement covers sale and distribution across the US and Europe, Middle East and Africa. Prior to US FDA approval, laboratories will have access to CARDIO inCode-Score as a lab developed test for the prevention of heart disease. Following approval, the collaboration will extend to manufacturing and sale of the device to laboratories and test centres across the US. The approach will be similar in the EMEA market. GENinCode current share price: 3.80 pence, closed up 27% in London on Thursday 12-month change: down 11% Thermo Fisher current share price: $573.08, down 1.3% in New York 12-month change: up 8.4% Copyright 2025 Alliance News Ltd. All Rights Reserved.
|
